News and Announcements
Analytica Limited Eyes $1.5 Million in New Renounceable Offer
- Published September 29, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Analytica has prepared a Prospectus, containing the details of the Entitlement Offer, and has sent this to eligible shareholders by September 28.
- Analytica Limited is set to raise $1.593 million as it undertakes a renounceable pro-rata entitlement offer to eligible shareholders with a registered address in New Zealand or Australia.
- Eligible shareholders can trade their rights to subscribe for new shares.
Analytica Limited expects to raise $1.593 million as it undertakes a renounceable pro-rata entitlement offer to eligible shareholders with a registered address in New Zealand or Australia. Shareholders with addresses outside of the two areas are considered ineligible shareholders.
The company decided not to extend the offer to ineligible shareholders considering the complexity, legal costs and requirements of specific authorities in other jurisdictions.
The entitlement offer, with an offer price of 0.5 cents for every new share, consists of one share for every eight existing shares held by a shareholder as of 7 p.m. on September 21.
Shareholders who intend to apply for the entitlement offer can opt for two Attaching Options: a share exercisable at 0.5 cents expiring on January 31, 2018, or a share exercisable at 0.5 cents expiring on May 31, 2018.
Eligible shareholders can apply for Additional Shares, or shares not subscribed by the other eligible shareholders. However, its allocation will be at the discretion of the directors and limited only to the number of shortfall shares. Successful applications will also have a dig at the Attaching Options.
The entitlements for the successful applicants under the offer are renounceable. Rights of the shareholders to subscribe for new shares and also the Attaching Options the ASX can be traded on ASX to any party from September 26 to October 5, the period stated for the rights trading period.
Analytica will add the fresh funds raised to its general working capital and use it to fund the PeriCoachTM System development. The company has 2,549,136,332 shares currently on issue and 318,642,042 shares under the offer of entitlement.
Analytica has prepared a Prospectus which contains all the offers being made. It also includes all details pertaining to the entitlement offer including the expenses related to the offer and the use of its proceeds.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
